Douleurs neuropathiques: contexte, nouveaux outils, nouveaux medicaments. [Neuropathic pains: background, new tools, new drugs]

Details

Ressource 1Download: RMS_43_2812.pdf (118.98 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_36CDEFBFE35E
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Douleurs neuropathiques: contexte, nouveaux outils, nouveaux medicaments. [Neuropathic pains: background, new tools, new drugs]
Journal
Revue Médicale Suisse
Author(s)
Kuntzer T., Decosterd I.
ISSN
1660-9379 (Print)
Publication state
Published
Issued date
11/2005
Peer-reviewed
Oui
Volume
1
Number
43
Pages
2812-6
Language
french
Notes
English Abstract Journal Article Review --- Old month value: Nov 30
Abstract
Neuropathic pains are frequent with better understood underlying mechanisms. The introduction of a new questionnaire, named DN4 (neuropathic pain 4 questions) will certainly be useful to prevent persistent pain. Here we describe current approaches to diagnosis and pharmacological treatments. Antidepressants, anticonvulsants, opioids and topical local anesthetics are part of the evidence-based approach, alone or in combination. The choice of the drug is based on the type of pain, a predominantly diffused pain being firstly treated with tricyclic antidepressants, whereas paroxysmal and localized pain being more adequately treated with anti-epileptics. Pregabaline, the newest anticonvulsant launched in the Swiss market, appears to be effective as a treatment of painful diabetic polyneuropathy and postherpetic neuralgia.
Keywords
Anesthetics/therapeutic use Anticonvulsants/*therapeutic use Antidepressive Agents/*therapeutic use Humans Narcotics/therapeutic use Nervous System Diseases/*complications Pain/*drug therapy/*etiology
Pubmed
Create date
25/01/2008 12:43
Last modification date
01/11/2024 14:06
Usage data